ClearBridge Investments’s Alexion Pharmaceuticals ALXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-5,866,154
| Closed | -$917M | – | 835 |
|
|
2020
Q4 | $917M | Sell |
5,866,154
-542,076
| -8% | -$69.7M | 0.71% | 30 |
|
|
2020
Q3 | $733M | Sell |
6,408,230
-491,377
| -7% | -$53M | 0.63% | 40 |
|
|
2020
Q2 | $774M | Buy |
6,899,607
+351,389
| +5% | +$37.3M | 0.7% | 35 |
|
|
2020
Q1 | $588M | Buy |
6,548,218
+185,429
| +3% | +$18.2M | 0.64% | 46 |
|
|
2019
Q4 | $686M | Buy |
6,362,789
+129,281
| +2% | +$13.8M | 0.57% | 52 |
|
|
2019
Q3 | $611M | Buy |
6,233,508
+227,311
| +4% | +$25.6M | 0.53% | 54 |
|
|
2019
Q2 | $787M | Buy |
6,006,197
+196,164
| +3% | +$25.3M | 0.68% | 36 |
|
|
2019
Q1 | $785M | Buy |
5,810,033
+665,574
| +13% | +$82.8M | 0.69% | 33 |
|
|
2018
Q4 | $501M | Sell |
5,144,459
-33,698
| -0.7% | -$3.98M | 0.51% | 53 |
|
|
2018
Q3 | $720M | Buy |
5,178,157
+691,390
| +15% | +$86.7M | 0.62% | 37 |
|
|
2018
Q2 | $557M | Buy |
4,486,767
+442,473
| +11% | +$51.7M | 0.46% | 59 |
|
|
2018
Q1 | $451M | Buy |
4,044,294
+502,423
| +14% | +$60.1M | 0.43% | 74 |
|
|
2017
Q4 | $424M | Buy |
3,541,871
+307,117
| +9% | +$37.4M | 0.39% | 82 |
|
|
2017
Q3 | $454M | Buy |
3,234,754
+171,703
| +6% | +$23.3M | 0.44% | 68 |
|
|
2017
Q2 | $373M | Buy |
3,063,051
+414,280
| +16% | +$48.2M | 0.37% | 79 |
|
|
2017
Q1 | $321M | Buy |
2,648,771
+377,098
| +17% | +$48.6M | 0.32% | 94 |
|
|
2016
Q4 | $278M | Buy |
2,271,673
+581,562
| +34% | +$71.2M | 0.31% | 99 |
|
|
2016
Q3 | $207M | Buy |
1,690,111
+297,204
| +21% | +$38.3M | 0.23% | 110 |
|
|
2016
Q2 | $163M | Buy |
1,392,907
+740,287
| +113% | +$105M | 0.19% | 124 |
|
|
2016
Q1 | $90.9M | Buy |
652,620
+567,165
| +664% | +$83.3M | 0.11% | 175 |
|
|
2015
Q4 | $16.3M | Buy |
85,455
+19,662
| +30% | +$3.43M | 0.02% | 436 |
|
|
2015
Q3 | $10.3M | Buy |
65,793
+10,259
| +18% | +$1.87M | 0.01% | 489 |
|
|
2015
Q2 | $10M | Buy |
55,534
+42,673
| +332% | +$7.36M | 0.01% | 502 |
|
|
2015
Q1 | $2.23M | Buy |
12,861
+944
| +8% | +$171K | ﹤0.01% | 673 |
|
|
2014
Q4 | $2.21M | Buy |
11,917
+195
| +2% | +$36.1K | ﹤0.01% | 694 |
|
|
2014
Q3 | $1.94M | Buy |
11,722
+1,471
| +14% | +$242K | ﹤0.01% | 705 |
|
|
2014
Q2 | $1.6M | Sell |
10,251
-313
| -3% | -$49.4K | ﹤0.01% | 692 |
|
|
2014
Q1 | $1.61M | Sell |
10,564
-3,747
| -26% | -$596K | ﹤0.01% | 695 |
|
|
2013
Q4 | $1.9M | Buy |
14,311
+1,611
| +13% | +$193K | ﹤0.01% | 667 |
|
|
2013
Q3 | $1.48M | Sell |
12,700
-5,590
| -31% | -$613K | ﹤0.01% | 672 |
|
|
2013
Q2 | $1.69M | Buy |
+18,290
| New | +$1.76M | ﹤0.01% | 639 |
|
Other funds holding ALXN
FCM
HI
PCM
DKCM
BBA
ClearBridge Investments's ALXN Position: Q1 2021 in Review
ClearBridge Investments sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 5,866,154 shares — an estimated $917M sold.
ClearBridge Investments first reported a position in ALXN in Q2 2013 and held it in 31 quarters. The position peaked at $917M in Q4 2020. 752 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.
- ClearBridge Investments reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
- ClearBridge Investments sold 5,866,154 Alexion Pharmaceuticals shares in Q1 2021, an estimated $917M.
- ClearBridge Investments first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 31 quarters.
- ClearBridge Investments's Alexion Pharmaceuticals position peaked at $917M in Q4 2020.
- 752 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.
Based on ClearBridge Investments's 13F filing for Q1 2021, filed 13 May 2021.